The global low endotoxin gelatin market was valued at USD 172.51 million in 2022. It is projected to reach USD 247.66 million in 2031, growing at a CAGR of 4.1% during the forecast period (2023–2031).
Gelatin is extracted from collagen—a non-allergen food ingredient—, which is a natural protein found in beef and pork, and sometimes fish (skin) and chicken (bones). It offers umpteen benefits, such as adjustable strength and high biocompatibility and biodegradability, which is further increasing the demand for gelatin across the medical sector. For the record, low endotoxin gelatin is derived from alkaline-treated porcine skin and is extensively used in the fields of regenerative medicine, drug delivery, medical devices, and tissue engineering research. The gelatin can also be used for creating UV-initiated and cross-linked scaffolds of any shape, which offers a wide range of mechanical properties and are suitable for many tissue engineering applications. Globally, increasing demand for better healthcare facilities and rising health care expenditure are some of the factors driving the market growth.
In the last few years, the major advances in stem cell research, regenerative medicine, and transplantation have completely revolutionized the medical sector. Similarly, new techniques are being introduced for combining cells with gelatin for developing new methods for repairing injured or diseased tissues and organs, such as scaffold for cells. Additionally, gelatin is recognized as safe by the U.S. Food and Drug Administration (FDA) for food processing. It is routinely used in the clinic as a plasma expander and a stabilizer in several protein formulations, including vaccines. Moreover, gelatin offers many benefits that make them highly favored in the biomaterial segment. Recently, gelatin-based micron and submicron particles have gained huge popularity in the field of biomolecules, drug delivery, and regenerative medicine. Some of the factors driving the market growth include increasing demand for biologically derived materials for regenerative medicine, growing organ transplantations, rising technological advancement, and growing government funding for the development of advanced therapies.
| Study Period | 2019-2031 | CAGR | 4.1% |
| Historical Period | 2019-2021 | Forecast Period | 2023-2031 |
| Base Year | 2022 | Base Year Market Size | USD XX Billion |
| Forecast Year | 2031 | Forecast Year Market Size | USD 247.66 Million |
| Largest Market | North America | Fastest Growing Market | North America |
North America is dominating the global low endotoxin gelatin market. This can be attributed to the rising demand for tissue regeneration procedures and increasing research in the application of stem cells. In the last few years, an extensive range of regenerative technologies has been updated for the repairing of diseased tissues and organs. Similarly, the rising emphasis on stem cell research in the U.S. and Canada is adding fuel to the market growth. The market is also majorly driven by the introduction of CAR-T cell therapies, development in material sciences, development of organic and inorganic substitutes, rising awareness of personalized medicine, and growing prevalence of road accidents and chronic diseases. As per the data published by the Insurance Institute for Highway Safety, in the U.S. alone, around 34,439 accidents and about 37,461 accident-related deaths occurred in 2016.
Apart from this, the growing prevalence of bone and joint diseases and rising demand for orthopedic surgeries are also supporting the market growth. Hemorrhage is another vital factor accelerating the demand for low endotoxin gelatin as it offers greater safety and aids in stopping the blood flow. Today, governments and private organizations across the globe are heavily investing in R&D activities to develop and produce low endotoxin gelatin coupled with advanced technological innovations in the healthcare industry.
The Middle East and Africa have the presence of some of the fastest developing economies that remain untapped. The market is expanding progressively and is creating abundant opportunities for new product launches. Some of the factors driving the market include the increasing prevalence of road accidents and chronic diseases, rising number of surgeries, increasing geriatric population, shifting disease demographics, growing demand for effective treatment, and rising R&D activities in the field of low endotoxin gelatin. However, lack of awareness and price sensitivity are restricting the growth to some extent.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Global Low Endotoxin Gelatin drug market is segmented by application.
By application, the market is further segmented into hemostatic applications, drug delivery and parenteral applications, and regenerative medicine.
Gelatin is extensively used for the manufacturing of hemostats in the form of sponges, strips, and powder or nanofibers. About 95% of the products are manufactured using acid porcine skin gelatin as it offers greater stability and better foaming properties. Similarly, lime bovine bone gelatins are also used for the manufacturing of hemostats. Globally, around 2 million people die from hemorrhage, and hemorrhage related wounds kill nearly 5 million people every year. In fact, severe bleeding accounts for about 80% of deaths in the operation theatre, which is further boosting the demand for homeostasis to stop the blood flow and promote blood clotting. However, the hemostatic solution must be used with extra care as the exposer of harmful endotoxins can trigger the immune response. Thus, low-endotoxin gelatins offer far greater safety in in-body applications like hemostatic.
Following are some of the key benefits of low-endotoxin gelatin:
To address the growing demand, a number of key players are excessively manufacturing highly purified, low endotoxin gelatins, such as Nitta Gelatin, Rousselot, and Gelita. Recently, Nitta Gelatin acquired Chicago’s Vyse Gelatin to expand its product portfolio. Similarly, Rousselot Biomedical’s X-Pure is an exceptionally safe gelatin solution for in-body hemostatic. It consists of a comprehensive range of high-purity gelatins and collagens and offers a wide range of acid porcine and lime bovine gelatins.
The COVID-19 pandemic has severely impacted various industry verticals for the entire first half of 2020 and is continuing to have its impact on the rest of the year as well. The industries have been shut down and workers sent home, resulting in halted production almost for the entire year. However, there has been a constantly emerging demand for work from home culture across the world is a significant factor for the growth of Continuous Performance Management. The advancement in technology has a considerable potential to meet the mounting scalable and growing data transmission requirement. The rising demand for performance monitoring interfaces explicitly used for mobile device computing is anticipated to create lucrative opportunities for universal Continuous Performance Management in the post-COVID-19 era.
Without data collection, subjective analysis becomes the basis for performance review, leading to overall imprecision and bias in performance management. Organizations are leveraging the wealth of available digital insights and embracing the power of business intelligence to make more informed decisions that would facilitate business growth and evolution.
Currently, most business-based decisions are backed by metrics, facts, or figures. Several companies are adopting and implementing various reporting tools for accurate analysis and measurement of data. For example, according to Sisense Inc., more data-driven organizations are at the top of their game than those whose decisions are driven by instincts. Therefore, different organizations attach importance to data-driven decision-making for employee performance management. According to Atiim Inc., only 8 % of companies consider the annual review to be beneficial in the case of employee performance management. The increasing need to improve business performance and the increasing adaptation of data-driven decision-making by organizations drives the demand for continuous performance management software.
